Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) to participate in upcoming investor conferences.
08/30/2023 - 08:00 AM
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Citi’s 2023 18 th Annual BioPharma Conference 1x1 Investor Meetings: Thursday, September 7, 2023 Location: Four Seasons Hotel, Boston, MA
H.C. Wainwright 25th Annual Global Investment Conference (Hybrid) Virtual Presentation: Monday, September 11, 2023 Location: Lotte New York Palace Hotel, New York, NY
Baird’s 2023 Global Healthcare Conference Presentation: Wednesday, September 13, 2023 at 9:05 am ET Location: Intercontinental New York Barclay, New York, NY
Morgan Stanley 21 st Annual Global Healthcare Conference Fireside Chat: Wednesday, September 13, 2023 at 4:15 pm ET Location: Sheraton Hotel, New York, NY
Live webcasts and archived replays of the presentation at the H.C. Wainwright 25th Annual Global Investment Conference and the fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference will be available on the investors section of www.vorbio.com .
About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com .
Contact:
Media & Investors Sarah Spencer +1 857-242-6076sspencer@vorbio.com
Vor Biopharma Inc
NASDAQ:VOR
VOR Rankings
#4827 Ranked by Stock Gains
VOR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VOR
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar